The Investor Education and Protection Fund (IEPF) Authority was set up under the Ministry of Corporate Affairs, as a statutory body under Companies Act 2013.
It aims to administer the Investor Education and Protection Fund with the objective of promoting Investor’s Education, Awareness and Protection.
Secretary Ministry of Corporate Affairs is the Chairperson of the Authority, Joint Secretary Ministry of Corporate Affairs is the Chief Executive Officer of the Authority.
The Authority takes various initiatives to fulfil its objectives through Investor Awareness Programmes and various other mediums like Print, Electronic, Social Media, and Community Radio etc.
FAME-II Scheme
Faster Adoption and Manufacturing of Hybrid and Electric Vehicles (FAME 2) is the part of the National Electric Mobility Mission Plan.
The Main thrust of FAME is to encourage electric vehicles by providing subsidies.
Under the scheme, the government plans to offer the incentives for electric buses, three-wheelers and four-wheelers to be used for commercial purposes.
The centre will invest in setting up charging stations, with the active participation of public sector units and private players.
FAME 2 will also encourage interlinking of renewable energy sources with charging infrastructure.
Arab League
Arab league is a regional organization of Arab countries in and around North Africa, the Horn of Africa and Arabia.
The Kingdom of Egypt, Kingdom of Iraq, Jordan, Lebanon, Saudi Arabia, and Syria are the founding members of the league.
Since 2011, Syria’s participation has been suspended after the Syrian Civil War.
Malaria Elimination Research Alliance
Indian Council of Medical Research initiated a co-operation termed Malaria Elimination Research Alliance.
The co-operation aims to bring various stakeholders on a single platform to identify and prioritize research work needed to meet the target to eliminate Malaria by 2030.
Shigellosis Vaccine
Shigellosis is an infectious disease caused by a group of bacteria called Shigella.
Most who are infected with Shigella develop diarrhoea, fever, and stomach cramps starting a day or two after they are exposed to the bacteria.
India has indigenously developed the first-ever vaccine for treatment for Shigellosis.
It is a dead vaccine, that is, it a dead germ of the bacteria causing disease would be introduced in the body so that the immune system develops immunity against it.
The disease, at present, is largely treated through antibiotics, but considering the fact that antibiotic resistance has become a major concern, the vaccine was the need of the hour.
